Twist Bioscience Corporation, a company that helps customers achieve success by leveraging their high-quality synthetic DNA on its silicon platform, today announced a partnership with Pure Biologics, to accelerate the development of new antibody-based immuno-oncology drugs.
“The unique methods and technical capabilities of Twist Bioscience enable the rapid creation of diverse synthetic libraries using modern and data-based randomization schemes. We expect that the potential of Twist Bioscience, combined with our activities in the field of immuno-oncology and scientific knowledge in the field of therapeutic bispecific antibodies and antibodies with fusion proteins, will allow us to accelerate the development of new drugs and create a basis for future research development, "said Dr. Filip Jelen, president of the company Pure Biologics SA.
Pursuant to the Twist Biopharma agreement, the Twist Bioscience division will provide Pure Biologics with access to selected libraries of phage display of synthetic antibodies obtained exclusively from sequences occurring in the human body and additionally optimized by the latest methods using, among others, artificial intelligence and big data analytics. Some of the libraries in the portfolio are specially selected for selected classes of biological targets, as well as increasing the potential for the production of bispecific antibodies. As part of the collaboration, Twist Bioscience and Pure Biologics will work on the discovery, validation and optimization of new antibody candidates for selected biological targets in immuno-oncology applications.
"We are delighted to be able to support Pure Biologics' immuno-oncology efforts with top-class bispecific antibodies identified and developed using our extraction and optimization engine," said Dr. Emily M. Leproust, CEO and co-founder of Twist Bioscience. 'The highly selective and potent action of bispecific antibodies, which bind to many biological targets, could lead to changes in cancer treatments in the future.'
